drugset
drugset / Trial / NCT03673111

Study of the Gut Hormone Analogue Y14 in Adult Subjects

NCT03673111 ↗

Phase 1 Completed 77 enrolled Imperial College London Covance · collabMedical Research Council · collab
RandomizedSequentialDouble-blindTreatment

Summary

A randomised, placebo controlled Phase I study to investigate investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of Y14 in adult subjects.

Timeline

Start
2017-04-10
Primary completion
2019-02-13
Completion
2019-02-13

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Y14 Peptide 1 mg Subcutaneous
Subject Y14 Peptide 2 mg Subcutaneous
Subject Y14 Peptide 6 mg Subcutaneous
Subject Y14 Peptide 9 mg Subcutaneous
Subject Y14 Peptide 18 mg Subcutaneous
Subject Y14 Peptide 26 mg Subcutaneous
Subject Y14 Peptide 36 mg Subcutaneous

Indications

diabetes mellitus obesity disorder